SQI Diagnostics Files for US IPO | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Canadian life science firm SQI Diagnostics has filed a preliminary prospectus to raise up to $30 million in an initial public offering in the US.

In a Form F-10 filed with the US Securities and Exchange Commission on Wednesday, the firm, which trades on the Toronto Stock Exchange, said that is has been approved for listing on NYSE Amex under ticker symbol "SQD."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.